All In Biotech

Drug Trial Radar · NCT06116045

Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder

Phase 2 Clinical Study to Evaluate the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Gel Form Applied to Women with Sexual Arousal Disorder

Last checked: Nov 19, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

30

Planned (sponsor's estimate)

Start

Oct 1, 2024

Primary completion

Feb 1, 2025

Study completion Mar 31, 2025

Sponsor

Lead sponsor
Biozeus Biopharmaceutical S.A.Industry
Sponsor type
Industry
First posted
Nov 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 21 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder.

Conditions

  • Female Sexual Arousal Disorder
  • Female Sexual Dysfunction

Interventions

  • BZ371A 7.5 mg (1.5 ml)Drug

    7.5 mg gel

  • BZ371A 5.0 mg (1.0 ml)Drug

    5.0 mg gel

  • BZ371A 2.5 mg (0.5 ml)Drug

    2.5 mg gel

  • Placebo (1.5 ml)Drug

    BZ371A-matched placebo

  • Placebo (1.0 ml)Drug

    BZ371A-matched placebo

  • Placebo (0.5 ml)Drug

    BZ371A-matched placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy in increasing arousalTime frame: Baseline, 4 weeks and 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centro de Pesquisa Clínica Multiusuário (CePeM)

    Rio de Janeiro, Rio de Janeiro, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.